The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
MJFF Research Grant, 2009Assessing Heart Rate Variability (HRV) in the Parkinson's Associated Risk Study (PARS) Cohort
Objective/Rationale:
The objective of this study is to determine if HRV, which is reduced in PD, is significantly reduced in subjects with hyposmia (loss of smell) compared to subjects who are... -
Rapid Response Innovation Awards, 2009Validating the Electrocardiogram as a Tool to Identify Pre-motor Parkinson's Disease
Promising Outcomes of Original Grant:
Our goal in the funded RRIA was to determine if a 5 minute EKG recordings in patients with a high probably of having pre-motor PD, i.e., individuals with... -
Research Grant, 2009Biomarkers of Pioglitazone Effects in Parkinson's Disease (BioPEP)
Objective/Rationale:
Pioglitazone is a medication used to treat diabetes that that has shown promise in laboratory studies for potentially slowing the progression of Parkinson’s disease (PD). The... -
Rapid Response Innovation Awards, 2009Enhanced Delivery of Viral Vectors to Striatum with Solid-State Biodegradable Matrices
Objective/Rationale:
When treating patients with neurological disorders, physicians frequently administer drugs through a small plastic tube or needle placed into the target area of the brain... -
Clinical Intervention Awards, 2009NIC-PD Trial to Assess the Disease-modifying Potential of Transdermal Nicotine in Early Parkinson's Disease
Objective/Rationale:
No drugs are available that can slow or stop the progression of Parkinson’s disease (PD). Nicotine is a promising substance for this purpose. Firstly, epidemiological studies... -
Understanding LRRK2 Biology, 2009Characterization of LRRK2 Cellular and Signaling Pathways
Objective/Rationale:
Mutations in LRRK2 are thus far the most common known cause of late-onset Parkinson’s disease (PD). The most prevalent LRRK2 mutation G2019S has been shown to stimulate LRRK2...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.